International award for research on self-management of diabetes
Sunderland-based researcher work on improving lives for people living with diabetes recognised.
A researcher from the University of Sunderland has received one of the highest recognitions for “outstanding” research on improving self-management of diabetes.
Dr Matthew Campbell, Principal Investigator in Cardiovascular and Metabolic Medicine, was recently named the recipient of the Elliot Johnson EASD PCL Biotech Award.
The annual award is presented in collaboration between the European Association for the Study of Diabetes (EASD) and global biosciences company PCL Biotech to an internationally established researcher who has made a career-defining contribution to applied diabetes research.
Dr Campbell’s work has aimed to help improve the lives of people with diabetes and he has published studies on diabetes and glucose regulation.
A recent study, looked at improving the health of people with type 1 diabetes with a simple lifestyle change, breaking up prolonged sitting with short frequent bouts of light-intensity walking.
Dr Campbell said: “It is an honour to receive this prestigious award and I dedicate it to the many colleagues, collaborators, students, and research participants who have contributed to the underpinning research – without their hard work and support this research would not have been possible.
“Importantly, this award shines a light on an important programme of clinical and applied research that is helping people with diabetes live a more fulfilled life. This work, much of which has originated, and been supported by, the University of Sunderland is contributing to shaping international healthcare policy.
“It has been fantastic to see first-hand how our research at Sunderland is benefiting local and global communities – underpinning the University’s core purpose of changing lives and shaping society.”
Image: Dr Matthew Campbell, Principal Investigator in Cardiovascular and Metabolic Medicine at the University of Sunderland
The criteria in the selection process for the award looked at the quality and significance of the candidates’ scientific contributions, and recognised the most innovative ideas in diabetes management, education, and patient care.
The award is named after Elliot Joslin, one of the first doctors to specialise in treating diabetes and pioneered work within lifestyle intervention and glucose control for reducing the risks of complications.
Henrik Schindler, Executive Vice President, Research and Early Development and Chief Scientific Officer at PCL Biotech, said: “We are delighted to award Dr Campbell the 2023 Elliot Johnson EASD PCL Biotech Award in recognition of his outstanding contribution to diabetes research.
“Dr Campbell has an extensive and established international record and his work has led to the development of innovative self-management solutions that have produced significant improvements in diabetes outcomes and patient quality of life. This award is an acknowledgement of his academic and professional contribution to the field of diabetes treatment and care specifically for his work investigating lifestyle intervention strategies for glucose control and cardiovascular disease prevention.”
Dr Campbell holds honorary titles at the Wellcome-MRC Institute of Metabolic Science (University of Cambridge), the Leeds Institute for Metabolic and Cardiovascular Medicine (University of Leeds), and Zhejiang Gongshang University. He is a scientific advisor for Diabetes UK, and the World Health Organisation. This year he was appointed among the first ever University of Sunderland Vice-Chancellor’s Research and Knowledge Exchange
Upon receipt of the award, Dr Campbell was named as an honorary professor at the Joslin Diabetes Center, Harvard University.
DRWF in the US has an endowed Chair, Dr Gordon Weir, at the Joslin Diabetes Center, the world’s first diabetes care centre and the global leader in diabetes research.
I would like to make a regular donation of
I would like to make a single donation of